Form 4 Intellia Therapeutics, For: Jun 17 Filed by: Verwiel Frank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq rise in choppy trading as tech steadies, Micron results in focus
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
June 24, 2024 12:15 PM EDTStifel analyst Dae Gon Ha reiterated a Buy rating and $80.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach and with the Ph.3 MAGNITUDE study ongoing, should be seen... More
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
June 24, 2024 9:49 AM EDTBaird analyst Jack Allen reiterated a Neutral rating and $24.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "No change to outlook on competitor's clinical data. This morning, Alnylam (ALNY, not covered) announced positive top-line results from the HELIOS-B study of their... More
